The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

More recent research has shown that the kidneys also bear glucagon receptors, but besides stimulating production of a minor amount of glucose, their role has been unclear, Dr. Scherer explained.

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

and this hormone binds to glucagon receptors in the liver. This binding stimulates breakdown of glycogen and the release of glucose into the circulation. Although glucose is the main mediator of ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...

NOVEL research has uncovered how a gut receptor, free fatty acid receptor 4 (Ffar4), influences sugar consumption preferences ...

For more information about INDIGO's GLP-1R, GIPR, and Glucagon Receptor Reporter Assays and other products and services, visit ...